UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

In a report published Friday, Stifel analyst Stephen Willey terminated coverage on Onyx Pharmaceuticals (NASDAQ: ONXX ). In the report, Stifel noted, “We are discontinuing coverage of Onyx Pharmaceuticals due to the company's acquisition by Amgen (AMGN, Covered by our Colleague Joel Sendek, Hold, $115.41) at $125.00 per share in